modelNimodipine

Diagram of Nimodipine

Extends from Pharmacolibrary.Drugs.ATC.C.C08CA06.

Information

name:Nimodipine
ATC code:C08CA06
route:oral
compartments:2
dosage:60mg
volume of distribution:0.94L
clearance:0.99L/h/kg
other parameters in model implementation

Nimodipine is a dihydropyridine calcium channel blocker used primarily to reduce the incidence and severity of neurological deficits arising from cerebral vasospasm following subarachnoid hemorrhage. Approved and used today mainly for this indication.

Pharmacokinetics

Pharmacokinetic parameters in healthy adult volunteers after oral administration.

References

  1. Mahmoud, SH, et al., & Isse, FA (2020). Nimodipine Pharmacokinetic Variability in Various Patient Populations. Drugs in R&D 20(4) 307–318. DOI:10.1007/s40268-020-00322-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32902829

  2. Kumana, CR, et al., & Lauder, IJ (1993). Investigation of nimodipine pharmacokinetics in Chinese patients with acute subarachnoid haemorrhage. European journal of clinical pharmacology 45(4) 363–366. DOI:10.1007/BF00265956 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8299671

  3. Terziivanov, D, et al., & Mück, W (1999). Pharmacokinetic variability of nimodipine disposition after single and multiple oral dosing to hypertensive renal failure patients: parametric and nonparametric population analysis. International journal of clinical pharmacology and therapeutics 37(8) 404–412. PUBMED:https://pubmed.ncbi.nlm.nih.gov/10475143

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)